Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of ...

With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer ...

Combination cut risk of recurrence or death by 28% in patients at high risk of relapse ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...

Built on Insights from Patients and Caregivers, the New Website Curates Trusted Resources from Leading Organizations in Kidney Cancer NUTLEY, N.J., Feb. 26, 2026 /PRNewswire/ -- Eisai Inc. announced ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

A 74-year-old man, diagnosed with advanced kidney cancer and facing an 80% damaged kidney, opted for natural treatment at ...

SAN FRANCISCO -- Despite a growing emphasis on quality-of-life (QoL) endpoints and patient-reported outcomes in cancer trials ...

Eisai has a position in kidney cancer with Lenvima (lenvatinib), a kinase inhibitor that is approved for use in combination with MSD's cancer immunotherapy Keytruda (pembrolizumab) as a first-line ...

Earlier analyses demonstrated strong local tumor control, with nearly nine in 10 patients remaining free of recurrence at ...

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when ...

Smoking may also promote kidney cancer in some indirect ways. For example, smoking can cause high blood pressure, which is another risk factor for kidney cancer. (More on that in a minute.) “This is ...